NC Medicaid and NC Health Choice
Pharmacy Prior Approval Request for
Hereditary Angioedema (HAE) Agents

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext._____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy (in days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days ☐ Other _____

Clinical Information

Prophylaxis Agents:
Requests for Cinryze:
1. Does the beneficiary have a diagnosis of hereditary angioedema (HAE) I or II and Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
2. Is this request for prophylaxis of acute HAE attacks? ☐ **Yes** ☐ **No**
3. Is the beneficiary at least 6 years of age? ☐ **Yes** ☐ **No**
4. Will it not be used in combination with other prophylactic therapies targeting C1 inhibitor (i.e., Haegarda, etc.) or kallikrein (i.e., Takhzyro, Orladeyo, etc.)? ☐ **Yes** ☐ **No**
5. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics ? ☐ **Yes** ☐ **No**
6. In addition, for non-preferred products, has the beneficiary tried and failed or experienced an insufficient response to at least two preferred products for the same indication or have a clinical reason that preferred products cannot be tried? ☐ **Yes** ☐ **No**

Requests for Haegarda:
7. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
8. Is this request for prophylaxis of acute HAE attacks? ☐ **Yes** ☐ **No**
9. Is the beneficiary at least 6 years of age? ☐ **Yes** ☐ **No**
10. Will it not be used in combination with other prophylactic therapies targeting C1 inhibitor (i.e., Cinryze, etc.) or kallikrein (i.e., Takhzyro, Orladeyo, etc.)? ☐ **Yes** ☐ **No**
11. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? ☐ **Yes** ☐ **No**

Requests for Orladeyo:
12. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
13. Is this request for prophylaxis of acute HAE attacks? ☐ **Yes** ☐ **No**
14. Is the beneficiary at least 12 years of age? ☐ **Yes** ☐ **No**
15 Will it not be used in combination with other prophylactic therapies targeting C1 inhibitor (i.e., Cinryze, Haegarda, etc.) or kallikrein (i.e., Takhzyro, etc.)? ☐ **Yes** ☐ **No**
16. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? ☐ **Yes** ☐ **No**

Requests for Takhzyro:
17. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
18. Is this request for prophylaxis of acute HAE attacks? ☐ **Yes** ☐ **No**
19. Is the beneficiary at least 2 years of age? ☐ **Yes** ☐ **No**
20. Will it not be used in combination with other prophylactic therapies targeting C1 inhibitor (i.e., Cinryze, Haegarda, etc.) or kallikrein (i.e., Orladeyo, etc.)? ☐ **Yes** ☐ **No**
21. In addition, for non-preferred products, has the beneficiary tried and failed or experienced an insufficient response to at least two preferred products for the same indication or have a clinical reason that preferred products cannot be tried? ☐ **Yes** ☐ **No**

Treatment Agents:
Requests for Berinert:
22. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
23. Does the beneficiary have a diagnosis of HAE with normal C1-INH (formerly known as HAE III); AND does the patient has a known HAE-causing mutation (e.g., mutation of coagulation factor XII gene [F12 mutation], mutation in the angiopoietin-1 gene, mutation in the plasminogen gene, mutation in the kininogen 1 gene, mutation in the myoferlin gene, mutation in the heparan sulfate 3-O sulfotransferase 6 gene, etc.)? ☐ **Yes** ☐ **No**
24. Is the request for treatment for acute abdominal, facial, or laryngeal attacks of HAE? ☐ **Yes** ☐ **No**

WellCare

NC Medicaid and NC Health Choice
Pharmacy Prior Approval Request for

25. Will it not be used in combination with other approved treatments for acute HAE attacks (e.g. Firazyr, Ruconest, and Kalbitor)? ☐ **Yes** ☐ **No**
26. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? ☐ **Yes** ☐ **No**

Requests for Firazyr:

27. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
28. Does the beneficiary has a diagnosis of HAE with normal C1-INH (formerly known as HAE III); AND does the patient has a known HAE-causing mutation (e.g., mutation of coagulation factor XII gene [F12 mutation], mutation in the angiopoietin-1 gene, mutation in the plasminogen gene, mutation in the kininogen 1 gene, mutation in the myoferlin gene, mutation in the heparan sulfate 3-O sulfotransferase 6 gene, etc.)? ☐ **Yes** ☐ **No**
29. Is the request for treatment of acute abdominal, facial, or laryngeal attacks of HAE? ☐ **Yes** ☐ **No**
30. Is the beneficiary at least 18 years of age? ☐ **Yes** ☐ **No**
31. Will it not be used in combination with, other approved treatments for acute HAE attacks (e.g. Berinert, Ruconest, and Kalbitor)? ☐ **Yes** ☐ **No**
32. In addition, for non-preferred products, has the beneficiary tried and failed or experienced an insufficient response to at least two preferred products or have a clinical reason that preferred products cannot be tried? ☐ **Yes** ☐ **No**

Requests for Kalbitor:

33. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
34. Does the beneficiary has a diagnosis of HAE with normal C1-INH (formerly known as HAE III); AND does the patient has a known HAE-causing mutation (e.g., mutation of coagulation factor XII gene [F12 mutation], mutation in the angiopoietin-1 gene, mutation in the plasminogen gene, mutation in the kininogen 1 gene, mutation in the myoferlin gene, mutation in the heparan sulfate 3-O sulfotransferase 6 gene, etc.) or family history of HAE? ☐ **Yes** ☐ **No**
35. Is the request for treatment of acute abdominal, facial, or laryngeal attacks of HAE? ☐ **Yes** ☐ **No**
36. Will it not be used in combination with, other approved treatments for acute HAE attacks (e.g. Berinert, Firazyr, and Ruconest)? ☐ **Yes** ☐ **No**
37. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? ☐ **Yes** ☐ **No**

Requests for Ruconest:

38. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? ☐ **Yes** ☐ **No**
39. Does the beneficiary has a diagnosis of HAE with normal C1-INH (formerly known as HAE III); AND does the patient has a known HAE-causing mutation (e.g., mutation of coagulation factor XII gene [F12 mutation], mutation in the angiopoietin-1 gene, mutation in the plasminogen gene, mutation in the kininogen 1 gene, mutation in the myoferlin gene, mutation in the heparan sulfate 3-O sulfotransferase 6 gene, etc.) or family history of HAE? ☐ **Yes** ☐ **No**
40. Is the request for treatment of acute abdominal or facial attacks of HAE? ☐ **Yes** ☐ **No**
41. Will it not be used in combination with, other approved treatments for acute HAE attacks (e.g. Berinert, Firazyr, and Ruconest)? ☐ **Yes** ☐ **No**
42. Will it be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? ☐ **Yes** ☐ **No**
43. In addition, for non-preferred products, has the beneficiary tried and failed or experienced an insufficient response to at least two preferred products for the same indication or have a clinical reason that preferred products cannot be tried? ☐ **Yes** ☐ **No**

Renewal Criteria for ALL AGENTS:

44. Does the beneficiary continue to meet the initial criteria? ☐ **Yes** ☐ **No**
45. Since starting the medication, has the beneficiary experienced significant improvement in severity and duration of attacks and ahs this improvement been sustained? ☐ **Yes** ☐ **No**
46. Has the beneficiary experienced any unacceptable toxicity from the medication? ☐ **Yes** ☐ **No**

Signature of Prescriber: _____ Date:_____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.